Primary Colorectal Cancer

Phillips E.H. Franklin M. Carroll B.J. et al.

Laparoscopic colectomy.

Ann Surg. 216: 703-707Lacy A.M. García-Valdecasas J.C. Delgado S. et al.

Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial.

Lancet. 359: 2224-2229Buunen M. Veldkamp R. Hop W.C. et al.

Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial.

Lancet Oncol. 10: 44-52Nelson H. Sargent D.J. Wieand H.S. et al.

A comparison of laparoscopically assisted and open colectomy for colon cancer.

N Engl J Med. 350: 2050-2059Fleshman J. Sargent D.J. Green E. et al.

Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial.

Ann Surg. 246 (): 655-662

Laparoscopic rectal cancer surgery: where do we stand?.

World J Gastroenterol. 18: 6747-6755Guillou P.J. Quirke P. Thorpe H. et al.

Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial.

Lancet. 365: 1718-1726van der Pas M.H. Haglind E. Cuesta M.A. et al.

Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial.

Lancet Oncol. 14: 210-218Fleshman J. Branda M. Sargent D.J. et al.

Effect of laparoscopic-assisted resection vs open resection of stage ii or iii rectal cancer on pathologic outcomes: the ACOSOG Z6051 randomized clinical trial.

JAMA. 314: 1346-1355Fleshman J. Branda M.E. Sargent D.J. et al.

Disease-free survival and local recurrence for laparoscopic resection compared with open resection of stage II to III rectal cancer: follow-up results of the ACOSOG Z6051 randomized controlled trial.

Ann Surg. 269: 589-595Stevenson A.R. Solomon M.J. Lumley J.W. et al.

Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: the ALaCaRT randomized clinical trial.

JAMA. 314: 1356-1363Kang S.B. Park J.W. Jeong S.Y. et al.

Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial.

Lancet Oncol. 11: 637-645Jayne D. Pigazzi A. Marshall H. et al.

Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical Trial.

JAMA. 318: 1569-1580Kim M.J. Park S.C. Park J.W. et al.

Robot-assisted versus laparoscopic surgery for rectal cancer: a phase II open label prospective randomized controlled trial.

Ann Surg. 267: 243-251Kapiteijn E. Marijnen C.A. Nagtegaal I.D. et al.

Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

N Engl J Med. 345: 638-646van Gijn W. Marijnen C.A. Nagtegaal I.D. et al.

Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial.

Lancet Oncol. 12: 575-582Sauer R. Becker H. Hohenberger W. et al.

Preoperative versus postoperative chemoradiotherapy for rectal cancer.

N Engl J Med. 351: 1731-1740Sauer R. Liersch T. Merkel S. et al.

Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

J Clin Oncol. 30: 1926-1933Ngan S.Y. Burmeister B. Fisher R.J. et al.

Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04.

J Clin Oncol. 30: 3827-3833Erlandsson J. Lörinc E. Ahlberg M. et al.

Tumour regression after radiotherapy for rectal cancer - Results from the randomised Stockholm III trial.

Radiother Oncol. 135: 178-186Erlandsson J. Holm T. Pettersson D. et al.

Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.

Lancet Oncol. 18: 336-346Bahadoer R.R. Dijkstra E.A. van Etten B. et al.

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.

Lancet Oncol. 22: 29-42Garcia-Aguilar J. Chow O.S. Smith D.D. et al.

Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.

Lancet Oncol. 16: 957-966Conroy T. Bosset J.F. Etienne P.L. et al.

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

Lancet Oncol. 22: 702-715Habr-Gama A. Perez R.O. Nadalin W. et al.

Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.

Ann Surg. 240 (): 711-717Habr-Gama A. São Julião G.P. Vailati B.B. et al.

Organ preservation among patients with clinically node-positive rectal cancer: is it really more dangerous?.

Dis Colon Rectum. 62: 675-683Rullier E. Vendrely V. Asselineau J. et al.

Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial.

Lancet Gastroenterol Hepatol. 5: 465-474van der Valk M.J.M. Hilling D.E. Bastiaannet E. et al.

Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.

Lancet. 391: 2537-2545Garcia-Aguilar J. Patil S. Gollub M.J. et al.

Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.

J Clin Oncol. 40: 2546-2556Jeong W.J. Choi B.J. Lee S.C.

Pure natural orifice transluminal endoscopic surgery for rectal cancer: Ta-TME and CME without abdominal assistance.

Asian J Surg. 42: 450-457Marks J.H. Salem J.F. Adams P. et al.

initial clinical experience with single-port robotic transanal total mesorectal excision (SP rTaTME).

Tech Coloproctol. 25: 721-726Zorron R. Phillips H.N. Wynn G. et al.

"Down-to-Up" transanal NOTES Total mesorectal excision for rectal cancer: Preliminary series of 9 patients.

J Minim Access Surg. 10: 144-150Rasulov A.O. Mamedli Z.Z. Dzhumabaev K.E. et al.

[Total mesorectal excision in rectal cancer management: laparoscopic or transanal?].

Khirurgiia (Mosk). : 37-44Zeng Z. Luo S. Chen J. et al.

Comparison of pathological outcomes after transanal versus laparoscopic total mesorectal excision: a prospective study using data from randomized control trial.

Surg Endosc. 34: 3956-3962Deijen C.L. Velthuis S. Tsai A. et al.

COLOR III: a multicentre randomised clinical trial comparing transanal TME versus laparoscopic TME for mid and low rectal cancer.

Surg Endosc. 30: 3210-3215Serra-Aracil X. Zárate A. Mora L. et al.

Study protocol for a multicenter prospective controlled and randomized trial of transanal total mesorectal excision versus laparoscopic low anterior resection in rectal cancer.

Int J Colorectal Dis. 33: 649-655

留言 (0)

沒有登入
gif